). Among HIV-seropositive patients, the only risk P p .57 factor for recurrent tuberculosis was a low median initial CD4 + T lymphocyte count (51 vs. 138 cells/mm 3 ; ). The median CD4 + T lymphocyte count among patients with ARR tuberculosis was 51 cells/mm 3 . P p .02 ARR tuberculosis can occur with rifampin-based regimens, but in this study, the risk was not significantly higher than that for a rifabutin-based regimen.
(DOT) is low in both HIV-infected and HIV-uninfected persons [1] [2] [3] [4] [5] . The risk factors associated with tuberculosis relapse in HIV-seronegative individuals include positive sputum culture results after 2 months of treatment, cavitation noted on a chest radiograph, bilateral pulmonary involvement, being underweight, and nonHispanic white race [6] [7] [8] . However, the risk factors for relapse among HIV-seropositive persons treated with rifamycin-based DOT have not been as well described [5, [9] [10] [11] .
Acquired rifamycin resistant (ARR) tuberculosis after treatment with rifamycin-based DOT has been reported in HIV-infected patients who received once-weekly rifapentine plus isoniazid or twice-weekly rifabutin plus isoniazid during the continuation phase of therapy [12, 13] . In both studies, patients with ARR tuberculosis had very low CD4 + T lymphocyte counts at the time that tuberculosis was diagnosed, suggesting that advanced immunosuppression may have played a role in the acquisition of rifamycin resistance. The risk of ARR tuberculosis appears to be low with either daily [5] or twice-weekly [9] regimens of rifampin plus isoniazid, but the latter regimen has not been well studied in HIV-seropositive persons. In addition, the risk of ARR tuberculosis associated with rifampin-based therapy has not been directly compared with the risk associated with rifabutin-based therapy. This is an important assessment, because
190% of initial antituberculosis drug regimens (regardless of the patient's HIV serostatus) in the United States include rifampin [14] .
We assessed the risk factors associated with relapse of tuberculosis and ARR tuberculosis in HIV-infected and HIVuninfected persons treated with rifamycin-based DOT, and we compared the risk of ARR tuberculosis between rifampin-based therapy and rifabutin-based therapy in HIV-seropositive persons.
METHODS
All patients with culture-confirmed tuberculosis who reported to the Baltimore City Health Department tuberculosis clinic during the period of 1 January 1993 through 31 December 2001 were eligible for inclusion in this observational cohort study. Exclusion criteria included diagnosis of tuberculosis at death, death during the course of treatment, receipt of rifapentine-based therapy, use of self-administered therapy for 150% of the duration of treatment, refusal to complete an appropriate course of therapy, loss to follow-up during treatment, relocation during treatment, or presence of rifamycinresistant disease at the time of initial diagnosis of tuberculosis.
Tuberculosis recurrence was defined as having an adequate response to tuberculosis treatment (including conversion of sputum culture results among persons with pulmonary tuberculosis) followed by a positive culture result during follow-up; false-positive culture results were excluded. Tuberculosis relapse was defined as a recurrence in which the restriction fragmentlength polymorphisms (RFLP; DNA fingerprint) of the Mycobacterium tuberculosis isolates from both the initial and recurrent episodes matched. ARR tuberculosis was defined as the development of rifamycin-resistant disease after having previously had rifamycin-susceptible disease. Follow-up for tuberculosis recurrence was done via passive surveillance through 31 December 2002.
Baseline mycobacterial cultures were performed at local hospital clinical microbiology laboratories using standard culture methods. Follow-up cultures were performed at the Maryland Department of Health and Mental Hygiene Mycobacteriology Laboratory (Baltimore); susceptibility testing was performed using the BACTEC radiometric method and the agar proportion method (Becton-Dickinson) [15, 16] . RFLP analysis was performed in the standard manner [17] [18] [19] [20] . M. tuberculosis isolates were considered to match if they had the same band pattern and number.
HIV diagnosis was established by a positive result of an ELISA for antibody to HIV-1 and confirmatory Western blot analysis. CD4 + T lymphocyte counts were determined by flow cytometry. HAART was defined as 3 nucleoside reversetranscriptase inhibitors or 2 nucleoside reverse-transcriptase inhibitors in combination with a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor.
DOT was provided by the Baltimore City Health Department staff throughout the entire course of treatment. All patients were treated with 15 daily doses of 4-drug therapy (typically isoniazid, rifampin or rifabutin, pyrazinamide, and ethambutol in standard doses) [21, 22] . Patients subsequently received twice-weekly 4-drug therapy for 6 weeks, followed by a course of twice-weekly isoniazid and rifampin or rifabutin; the duration of therapy was determined by the clinician and on the basis of the site of tuberculosis disease.
The x 2 test or Fisher's 2-tailed exact test was used to compare categorical variables, and the Mann-Whitney U test was used to compare continuous variables. Statistical analysis was performed using Stata, version 6.0 (Stata). The protocol was reviewed by the Johns Hopkins Joint Committee on Clinical Investigation (Baltimore).
RESULTS
There were 618 patients with cases of culture-confirmed tuberculosis reported to the Baltimore City Health Department during the study period. Of these, 211 patients were excluded for the following reasons: tuberculosis was diagnosed at death or death occurred during the course of treatment (138 patients), patient received rifapentine-based therapy (24 patients) or selfadministered therapy (16 patients), patient refused to complete an appropriate course of therapy (13 patients), patient was lost to follow-up during treatment (10 patients), patient relocated during treatment (7 patients), and patient had rifamycinresistant disease at the time of initial diagnosis of tuberculosis (3 patients). Of the remaining 407 persons, 108 (27%) were HIV seropositive, 161 (40%) were HIV seronegative, and 138 (34%) had an unknown HIV serostatus. The baseline characteristics of the 407 persons included in this study, stratified by HIV serostatus, are in table 1. Because demographic and clinical variables did not differ between HIV-seronegative persons and those with unknown HIV serostatus, with the exception of median age (47 vs. 58 years;
), these 2 groups were P ! .001 combined (hereafter referred to as "HIV-seronegative/unknown patients").
There were 14 episodes (3.4%) of recurrence: 9 (8.3%) oc- ). When persons with pulmonary disease only were P p .04 considered, recurrence occurred in 5 (7%) of 71 HIV-seropositive patients and 4 (1.7%) of 241 HIV-seronegative/unknown patients (
). There were no episodes of recur-P p .03 rence among persons with extrapulmonary disease only, regardless of HIV serostatus. The median time to recurrence (measured from the day tuberculosis therapy was stopped to the day that a recurrent positive culture result was obtained) was 203 days; it was 157 days among HIV-seropositive patients and 436 days among HIV-seronegative/unknown patients ( ). Non-Hispanic white race, presence of cavitary pul-P p .21 monary tuberculosis, and sputum culture positivity after 2 months of antituberculosis therapy were predictive of recurrence in HIV-seronegative/unknown patients but not in HIVseropositive patients (table 2). In the latter group, only initial CD4 + T lymphocyte count predicted recurrence (table 2) . DNA fingerprinting data were available for the initial and recurrent M. tuberculosis isolate for 9 of 14 episodes of recurrence, and, in all 9 episodes, the second isolate matched the original isolate, which is consistent with relapse.
There were 3 cases of ARR tuberculosis among the 108 HIVseropositive patients, for a rate of 2.8%, but there were none among the 299 HIV-seronegative/unknown patients ( ). P p .02 When comparing only patients in whom HIV serostatus was known, HIV-seropositive individuals were more likely to develop ARR tuberculosis than were HIV-seronegative patients (2.8% vs. 0%;
). All 3 episodes of ARR tuberculosis P p .06 were confirmed to be relapses by DNA fingerprinting. The median CD4 + T lymphocyte count for these 3 patients was 51 cells/mm 3 . One of the 3 patients had both extrapulmonary and pulmonary disease, but none had cavitary pulmonary disease or positive sputum culture results after 2 months of therapy. The median time to relapse among those with ARR tuberculosis was 157 days, compared with 150 days among HIV-seropositive patients who developed recurrent tuberculosis without ARR ( ). All 3 patients who developed ARR tuberculosis re-P p .8 ceived rifampin-based therapy.
HIV-seropositive patients who received rifabutin were more likely to have received concomitant HAART than were those who received rifampin (table 3) . Although the rates of recurrence and ARR tuberculosis were higher among HIV-seropositive persons receiving rifampin than among those receiving rifabutin, these differences were not statistically significant (table 3).
One of the 3 individuals with ARR tuberculosis received rifabutin as prophylaxis against disseminated Mycobacterium avium complex disease 1 month after completing rifampinbased therapy for tuberculosis, as reported previously [23] . After 3 months of rifabutin prophylaxis, the patient had relapse of ARR tuberculosis. Because it is therefore unclear whether ARR tuberculosis was related to rifamycin therapy for the treatment of tuberculosis or the prevention of M. avium complex, or both, the analyses were also conducted with this case excluded. The results were unchanged. 
DISCUSSION
To our knowledge, this is the first study to compare the risk of ARR tuberculosis among HIV-seropositive persons treated with twice-weekly directly observed rifampin or rifabutin plus isoniazid in the continuation phase of therapy. In 3 randomized trials, rifampin-and rifabutin-based therapy had equal efficacy among both HIV-seropositive and HIV-seronegative patients with tuberculosis, but none of these studies commented on the acquisition of rifamycin resistance [24] [25] [26] . In our study, HIVseropositive patients treated with twice-weekly rifampin had higher rates of relapse and ARR tuberculosis than did patients treated with twice-weekly rifabutin, but the differences were not statistically significant. The rate of ARR tuberculosis in HIV-seropositive persons treated with twice-weekly rifampin (3 [3.7%] of 81 patients) was higher than that seen in studies involving HIV-seronegative adults treated with twice-weekly rifampin-based therapy (1 [0.2%] of 502 patients) [8] and among HIV-seronegative and HIV-seropositive adults treated with daily rifampin-based therapy (0 of 175 HIV-seronegative patients and 0 of 151 HIV-seropositive patients) [5] . In a small study of HIV-seropositive patients with tuberculosis who were treated with twice-weekly rifampin plus isoniazid in the continuation phase, 3 of 31 patients had relapse, but none developed ARR tuberculosis [12] . The results of our study suggest that ARR tuberculosis can occur with highly intermittent rifampin-based regimens, just as it has been reported to occur with highly intermittent rifabutin-based (or rifapentine-based) regimens [12, 13] . To confirm that the risk of ARR tuberculosis is indeed lower with daily therapy, however, studies that directly compare daily and intermittent therapy are needed. ARR tuberculosis occurred only in HIV-seropositive persons with low CD4 + T lymphocyte counts (median, 51 cells/mm 3 ) in this study, which is consistent with previous studies. In US Public Health Service Study 22 [12] , the 4 people whose infections acquired rifamycin resistance had a median CD4 + T lymphocyte count of 16 cells/mm 3 , and in US Public Health Service Study 23 [13] , the 5 people whose infections acquired rifamycin resistance all had CD4 + T lymphocyte counts of !60 cells/mm 3 at the time that tuberculosis was diagnosed.
Our study also further delineated risk factors associated with tuberculosis recurrence and relapse in HIV-infected and HIVuninfected persons treated with rifamycin-based DOT. Among HIV-seronegative/unknown patients, positive sputum culture results at 2 months, cavitation noted on a chest radiograph, and non-Hispanic white race were associated with relapse, which is consistent with the findings of a recent study [8] . Among HIV-positive patients in our study, only low initial CD4 + T lymphocyte count predicted relapse. This is consistent with a previous study of HIV-seropositive persons treated with daily rifamycin-based therapy (although therapy was self- administered rather than directly observed), in which there was a suggestion that the risk of relapse was higher in persons with CD4 + T lymphocyte counts of !100 cells/mm 3 [9] . The relatively small sample size of HIV-infected patients in our study may have contributed to the inability to detect other predictors of relapse in this group. However, the proportion of HIVinfected patients with positive sputum culture results at 2 months or cavitation noted on a chest radiograph was actually higher among those who did not have relapse than among those who did, suggesting that these factors may not be as important in predicting relapse in HIV-seropositive patients as they are in HIV-seronegative patients.
In our cohort, there was a higher rate of recurrent tuberculosis among HIV-seropositive patients than has been noted in previous studies of rifamycin-based DOT, and there were significantly more relapses among the HIV-seropositive patients than among the HIV-seronegative/unknown patients. This may be a result of both the larger sample size and the population studied. In an earlier, smaller study from our database (which included some of the patients in the current study), HIVseropositive patients had a higher relapse rate than did HIVseronegative/unknown patients, but the difference was not statistically significant (6.4% vs. 3.0%;
) [4] . In the current, P p .38 larger study, rates of tuberculosis recurrence were significantly different (8.3% vs. 1.7%;
). It is important to note, P p .003 however, that the first study included persons with culturenegative disease (which accounted for 22% of the entire cohort). Culture-negative tuberculosis probably has a lower bacillary burden than does culture-positive disease and, therefore, could be associated with a lower risk of relapse. In the current study, we included only persons with culture-confirmed tuberculosis, to ensure that all persons had baseline M. tuberculosis isolates that were susceptible to rifamycins.
The median time to complete therapy was longer for HIVseropositive patients than for HIV-seronegative/unknown patients (32.6 vs. 29.7 weeks;
). This measurement in-P p .05 cludes delays in therapy, which are often more frequent in HIV-infected persons because of drug-drug interactions and higher adverse event rates. The total amount of treatment received would have been a better comparison of treatment duration, but these data were not readily available for all patients. However, the recommended duration of therapy was the same for both HIV-seropositive and HIV-seronegative persons (i.e., 6 months for pulmonary disease) throughout the study period.
There are several limitations of this study. First, follow-up for tuberculosis recurrence was passive and included only those cases that were reported in the state of Maryland; therefore, rates of relapse and ARR tuberculosis could have been underestimated. Second, the HIV serostatus was unknown for onethird of our study population. However, patients with unknown HIV serostatus were very similar demographically to the HIVseronegative patients, and the results did not differ when those with unknown HIV serostatus were excluded. Third, the sample size was small, particularly for HIV-seropositive patients. Additional studies involving persons treated with rifampin versus rifabutin will help clarify whether the risk of ARR tuberculosis is equivalent for these 2 drugs. Finally, HAART use was more common among persons treated with rifabutin than among those treated with rifampin, which could have affected the risk of relapse and ARR tuberculosis. Additional studies of the impact of HAART on the risk of ARR tuberculosis are needed.
This study confirms that, among HIV-infected patients with tuberculosis receiving highly intermittent isoniazid and rifamycin treatment in the continuation phase of therapy, low CD4 + T lymphocyte count is the most important risk factor for relapse and acquired rifamycin resistance. The data demonstrate that ARR tuberculosis can occur with rifampin-based regimens, although it is unclear whether the risk differs from that seen among persons treated with a rifabutin-based regimen.
